Skin Diseases, Infectious  >>  Cubicin (daptomycin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
NCT01211470 / 2011-003741-17: Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus

Completed
2
215
Canada, RoW
Daptomycin, PMX-30063-investigational drug
PolyMedix, Inc.
Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA), (Susceptible or Methicillin Resistant)
12/11
03/12
NCT02052388: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Completed
2
215
US
Daptomycin, Cubicin, Brilacidin, PMX63
Cellceutix Corporation
Skin Infection, Bacterial Infection
10/14
10/14

Download Options